A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Bevacizumab
  • Neoplasm Recurrence, Local
  • Prostatic Neoplasms
  • Vascular Endothelial Growth Factor A

abstract

  • ADT combined with bevacizumab resulted in an improved RFS for patients with hormone-sensitive prostate cancer. Long-term follow-up is needed to determine whether some patients have a durable PSA response and are able to remain off ADT for prolonged periods. Our data provide rationale for combining vascular endothelial growth factor-targeting therapy with ADT in hormone-sensitive prostate cancer.

publication date

  • June 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5321094

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.65.3154

PubMed ID

  • 27044933

Additional Document Info

start page

  • 1913

end page

  • 20

volume

  • 34

number

  • 16